Drugs / Meloxicam
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Zynrelef | — | 2023-10-05 | europa.eu ↗ |
| Approved | EU (EMA) | Zynrelef | — | 2020-09-24 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | MOBIC | — | 2004-07-16 – 2005-08-11 | fda.gov ↗ |
| Approved | US (FDA) | MOBIC | — | 2000-04-13 | fda.gov ↗ |
Trials 87 · started per year
today
US approved 2000
EU approved 2020
6
3
3
4
3
7
1
1
2
1
3
1
6
4
2
3
3
6
4
3
2
5
7
3
2
1
1
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06349772 | Nov 2024 → Nov 2027 expected | — | Texas Tech University Health Sciences Center | Recruiting | No outcome recorded |
| Phase 119 trials | ||||||
| Phase 1 | NCT05181124 | Mar 2021 | active peptic ulcer disease | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04490434 | Jun → Aug 2020 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04322175 | Dec 2019 → Jun 2020 | — | Beijing Tongren Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03684265 | Oct 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03354117 | Mar 2018 → May 2019 | — | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT05125588 | Jan → Feb 2014 | — | Joint Stock Company "Farmak" | Completed | No outcome recorded |
| Phase 1 | NCT01839643 | Jan → May 2013 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00731302 | Apr 2005 → Apr 2017 | systemic lupus erythematosus | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00649675 | Aug → Sep 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649077 | Aug → Sep 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00840879 | Feb 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00840476 | Feb 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT02187562 | Jul → Aug 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02181309 | Jan → Apr 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02181322 | Jun → Sep 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02183142 | Mar → Apr 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02276352 | Jun → Aug 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02183103 | Apr → May 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02183077 | Sep → Nov 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06403046 | Jun 2024 → May 2025 | temporomandibular joint disorder | Beni-Suef University | Completed | No outcome recorded |
| Phase 1/2 | NCT04398329 | May 2020 → Jul 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT05950152 | Jul → Dec 2023 | neuropathy, painful | Beijing Tide Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT05695352 | Jun 2022 → Nov 2024 | — | InnovaGyn, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04911062 | Apr → Jul 2022 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT04115098 | Jun 2020 → Aug 2023 | spondyloarthropathy | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| Phase 2 | NCT03695367 | Oct → Nov 2018 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02540265 | Aug → Nov 2015 | — | Baudax Bio | Completed | No outcome recorded |
| Phase 2 | NCT02405793 | May → Jul 2015 | osteoarthritis | Iroko Pharmaceuticals, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT02078102 | Mar 2014 → Nov 2018 | non-Hodgkin lymphoma, plasma cell myeloma | Sherif S. Farag | Completed | No outcome recorded |
| Phase 2 | NCT02003625 | Oct 2013 → Feb 2019 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01799213 | Sep 2013 → Oct 2018 | osteoarthritis, knee | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT01346137 | Jan → Apr 2011 | — | Instituto Chileno de Medicina Reproductiva | Unknown | No outcome recorded |
| Phase 2 | NCT01084161 | Mar 2010 → Jan 2011 | — | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00945763 | Jul → Nov 2009 | — | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02183038 | Jul 1998 → Feb 1999 | pharyngitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02183051 | Apr → Oct 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02183025 | Jan 1998 → Apr 1999 | primary dysmenorrhea | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02255045 | Jun 2014 → Feb 2016 | primary dysmenorrhea | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 332 trials | ||||||
| Phase 3 | NCT06904248 | Jan → Nov 2024 | — | Yangtze River Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT07463404 | Dec 2023 → Jun 2025 | temporomandibular joint disorder | Suez Canal University | Completed | No outcome recorded |
| Phase 3 | NCT06379165 | May → Jul 2023 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05751421 | Feb 2023 → Feb 2024 | neuropathy, painful | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT05702827 | Jan 2023 → Mar 2024 | female stress incontinence, vulvar disease | TriHealth Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05550207 | Aug 2022 → Nov 2024 | migraine disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05291598 | May 2022 → May 2023 | — | University of Miami | Completed | No outcome recorded |
| Phase 3 | NCT04725357 | Jan 2021 → Jan 2022 | arthropathy | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT04163185 | Oct 2019 → Mar 2020 | migraine disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04068051 | Jul 2019 → Sep 2020 | migraine disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03936192 | Jan 2019 → Feb 2021 | osteoarthritis, knee | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT03586934 | Jun 2018 → Jun 2019 | substance-related disorder | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT03434275 | Feb 2018 → May 2019 | — | Baudax Bio | Completed | No outcome recorded |
| Phase 3 | NCT03295721 | Oct 2017 → Jan 2018 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03323385 | Oct 2017 → Sep 2018 | neuropathy, painful | Baudax Bio | Completed | No outcome recorded |
| Phase 3 | NCT02720692 | Mar 2016 → Mar 2017 | — | Baudax Bio | Completed | No outcome recorded |
| Phase 3 | NCT02678286 | Jan → Oct 2016 | neuropathy, painful | Baudax Bio | Completed | No outcome recorded |
| Phase 3 | NCT02675907 | Jan → Jul 2016 | — | Baudax Bio | Completed | No outcome recorded |
| Phase 3 | NCT02060006 | Apr 2014 → Apr 2015 | tuberculosis | University of Stellenbosch | Unknown | No outcome recorded |
| Phase 3 | NCT01979510 | Nov 2013 → May 2014 | — | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT01801735 | Mar 2013 → Jun 2014 | osteoarthritis | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01787188 | Feb → Oct 2013 | osteoarthritis | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02706054 | May 2012 → Jul 2014 | — | Rizzoli Orthopaedic Institute | Completed | No outcome recorded |
| Phase 3 | NCT01436032 | Oct 2011 → Mar 2012 | — | Alkermes, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00239382 | Jul → Dec 2004 | rheumatoid arthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00239395 | Jul → Dec 2004 | osteoarthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00152919 | Feb 2004 → May 2009 | prostate neoplasm | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT00042068 | Jun 2002 → Jul 2003 | rheumatoid arthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02183168 | Jul 2001 → May 2002 | ankylosing spondylitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00034853 | Dec 2000 → Jun 2003 | juvenile idiopathic arthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00279747 | Sep 2000 → Jan 2003 | juvenile idiopathic arthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02183064 | Oct 1998 → Nov 2000 | osteoarthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT07216586 | Jan 2027 → Jan 2028 expected | osteoarthritis, knee | University of Miami | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07430085 | Jul 2026 → Jan 2028 expected | osteoarthritis, knee | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07200544 | Oct 2025 → Jun 2026 overdue | skin cancer | University of Oklahoma | Recruiting | No outcome recorded |
| Phase 4 | NCT07076069 | Jul 2025 → Jun 2028 expected | rotator cuff syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05863221 | May 2023 → Oct 2024 | — | Dr. Yannis Raftopoulos | Unknown | No outcome recorded |
| Phase 4 | NCT05644496 | Mar 2023 → Dec 2025 | osteoarthritis, knee | Baptist Health South Florida | Terminated | No outcome recorded |
| Phase 4 | NCT05315479 | Feb → Jul 2022 | — | Baudax Bio | Terminated | No outcome recorded |
| Phase 4 | NCT02298218 | Sep 2009 → Jun 2011 | biliary atresia | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00635349 | May 2007 → Apr 2009 | osteoarthritis | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 4 | NCT02229747 | Aug 2001 → Feb 2002 | pharyngitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02183155 | May → Sep 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02183129 | Apr → Nov 1999 | osteoarthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02183116 | Oct 1998 → Feb 1999 | osteoarthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT04176783 | Mar 2018 → Jul 2021 | — | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| — | NCT04003350 | Dec 2017 → Nov 2018 | osteoarthritis, knee | Rothman Institute Orthopaedics | Completed | No outcome recorded |
| — | NCT01430559 | Oct 2011 → Mar 2013 | osteoarthritis, knee | Pfizer | Completed | No outcome recorded |
Also used as a comparator or background therapy in 24 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06902090 Comparator | Jul 2023 | — | Yangtze River Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02183090 Comparator | Nov → Dec 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06306131 Comparator | Dec 2023 → Nov 2025 | — | InnovaGyn, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02456363 Background | Nov 2009 → Oct 2019 | ankylosing spondylitis | Chung Shan Medical University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04480359 Comparator | Oct 2017 → Aug 2020 | ankylosing spondylitis | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT07549386 Comparator | May 2024 → Mar 2025 | osteoarthritis | Laboratorios Liomont | Completed | No outcome recorded |
| Phase 3 | NCT03907176 Background | Apr 2019 → Oct 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03896009 Comparator | Mar → Dec 2019 | migraine disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03146000 Comparator | May 2017 → Aug 2018 | puerperal disorder | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02448199 Comparator | Jul 2015 → Jun 2016 | osteoarthritis | Zodiac Produtos Farmaceuticos S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT01789216 Comparator | Jul 2013 → Dec 2018 | — | Major Extremity Trauma Research Consortium | Completed | No outcome recorded |
| Phase 3 | NCT01587508 Comparator | May 2013 | — | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01147289 Comparator | Feb → Nov 2011 | sciatica | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07158476 Comparator | Oct 2025 → Sep 2030 expected | — | St. Louis University | Recruiting | No outcome recorded |
| Phase 4 | NCT06704113 Comparator | Dec 2024 → Jan 2025 overdue | dental pulp disorder, perceptual disorders | Universidad Austral de Chile | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05974501 Background | Sep 2023 → Jan 2024 | osteoarthritis, knee | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT04766996 Background | May → Dec 2021 | substance-related disorder | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT03473665 Comparator | Mar 2018 → Aug 2019 | ankylosing spondylitis | Columbia University | Terminated | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07493226 Comparator | Apr 2026 → Feb 2027 expected | frozen shoulder, neuropathy, painful | Konya Beyhekim Training and Research Hospital | Recruiting | No outcome recorded |
| — | NCT07462988 Comparator | Jan → Jun 2025 | — | Istanbul Medeniyet University | Completed | No outcome recorded |
| — | NCT05672784 Comparator | Nov 2022 → Dec 2024 overdue | — | Zagazig University | Recruiting | No outcome recorded |
| — | NCT05097768 Comparator | Aug 2021 → Jan 2022 | pulpitis | Alfarabi Colleges | Completed | No outcome recorded |
| — | NCT04538391 Comparator | Mar 2019 → Mar 2020 | — | Menoufia University | Completed | No outcome recorded |
| — | NCT01638962 Comparator | Aug 2012 → Aug 2015 | osteoarthritis, knee | University of Southern Denmark | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-18 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain viatris.com ↗ |
| 2025-08-01 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference viatris.com ↗ |
| 2025-05-08 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain viatris.com ↗ |
| 2006-07-20 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval of Meloxicam Tablets tevapharm.com ↗ |
Evidence & citations 43 cited values
Every value below carries the sentence it was read from. 114 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | meloxicam | “Specific Aim 3: Estimate the incremental cost effectiveness of each adjunctive analgesic therapy relative to standard of care analgesic therapy in the treatment of severe limb...” NCT01789216 ↗99“The aim of the study was to compare the bioavailability of two formulations of meloxicam given to healthy volunteers and to demonstrate bioequivalence. The test product,...” NCT05125588 ↗ “The study aims to design a randomized controlled trial that compares the effect of intra-articular injection of the non-selective (NSAID) Tenoxicam versus the selective COX-2...” NCT06403046 ↗ “The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two...” NCT06349772 ↗ “ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated...” NCT05863221 ↗ “Acetaminophen 975mg every 4 hours, Meloxicam 7.5mg once per day, Pregabalin 50mg twice per day, Magnesium 400mg once per day, along with rescue Oxycodone 5mg every 4 hours, as needed” NCT07076069 ↗ “Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers” NCT02276352 ↗ “Each study participant will receive one dose of the study medication (ulipristal acetate 30mg plus meloxicam 15mg) at peak fertility in the treatment cycle.” NCT03354117 ↗ “A single 14 mL dose of HTX-011 containing 400 mg bupivacaine and 12 mg meloxicam will be applied intraoperatively to the surgical site.” NCT07216586 ↗ “Patients randomized into this group (n=40) will, again by simple randomization, be given oral tablets of meloxicam or lornoxicam” NCT07493226 ↗ “Inject Combination of Platelet-Rich Plasma and Cyclooxygenase Enzyme-2 Inhibitor meloxicam (Mobitil 15mg) after arthrocentesis” NCT07463404 ↗ “HTX-011 (bupivacaine and meloxicam in Biochronomerpolymer technology), an extended-release, dual-acting local anesthetic” PMID 31113830 ↗ May 2019 “HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.” NCT04911062 ↗ “AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.” NCT04068051 ↗ “medications such as Gabapentin, Tylenol, Meloxicam, Bupivacaine, or Ketorolac.” NCT04176783 ↗ “Bupivacaine Versus Meloxicam Infiltration on Post Cesarean Section Pain Relief” NCT04538391 ↗ “HTX-034 (bupivacaine/aprepitant/meloxicam) fixed dose: 21.7 mg/4.3 mg/0.6 mg” NCT04398329 ↗ “HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.” NCT03695367 ↗ “DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg)” NCT01979510 ↗ “N1539 (meloxicam injection for IV use)” NCT03434275 ↗ “300 mg bupivacaine/9 mg meloxicam” NCT03907176 ↗ “Meloxicam” NCT01638962 ↗ |
| Known as | Acticam | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | ANJESO | “Meloxicam Nanocrystal Injection (ANJESO®)” NCT06902090 ↗ |
| Known as | Anticox | “meloxicam 15mg (Anticox 2 ampoule 15mg/3ml, ADWIA Pharmaceuticals)” NCT04538391 ↗ |
| Known as | Contacera | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Coxicam | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Drug: Mobic | “Drug: Mobic” NCT02456363 ↗ |
| Known as | Emdocam | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Flexicam | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Inflacam | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Loxicom | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Loxitab | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Melfax | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Melosus | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Melovem | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Meloxicam component of zeleris | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Meloxicam component of zynrelef | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | MELOXICAM SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Meloxicam/Mobic (NDC 68382-000-01; manufacturer: Zydus; encapsulated in size AA | “Meloxicam/Mobic (NDC 68382-000-01; manufacturer: Zydus; encapsulated in size AA” NCT01789216 ↗ |
| Known as | Meloxidolor | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Meloxidyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Meloxivet | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Meloxoral | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Metacam | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Mobic | “The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15...” NCT00649077 ↗3“Mylan's meloxicam 15 mg tablets and Boehringer Ingelheim's Mobic® 15 mg tablets” NCT00649675 ↗ “Drug: Mobic” NCT02456363 ↗ |
| Known as | Mobitil | “Inject Combination of Platelet-Rich Plasma and Cyclooxygenase Enzyme-2 Inhibitor meloxicam (Mobitil 15mg) after arthrocentesis” NCT07463404 ↗ |
| Known as | Movalis | “The aim of the study was to compare the bioavailability of two formulations of meloxicam given to healthy volunteers and to demonstrate bioequivalence. The test product,...” NCT05125588 ↗ |
| Known as | Movatec | “Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose.” NCT01147289 ↗1“meloxicam - Movatec®” NCT01587508 ↗ |
| Known as | N1539 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02678286 ↗ |
| Known as | Novaquin | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Novem | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Qmiiz odt | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Recocam | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Reumoxicam | “The aim of the study was to compare the bioavailability of two formulations of meloxicam given to healthy volunteers and to demonstrate bioequivalence. The test product,...” NCT05125588 ↗ |
| Known as | Revitacam | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Rheumocam | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | SoluMatrix meloxicam | “SoluMatrix meloxicam has been developed with the goal of enabling effective treatment at low doses.” PMID 26503347 ↗ Dec 2015 |
| Known as | UH-AC 62XX | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Known as | Vivlodex | ChEMBL registry synonym — accepted as the source's own label CHEMBL599 ↗ |
| Action | Inhibit | “a cyclooxygenase-2 (COX-2) inhibitor regimen” PMID 20350785 ↗ Mar 20101“Cyclooxygenase-2 inhibitor” CHEMBL599 ↗ |
| Modality | Small molecule | “Nonsteroidal anti-inflammatory medication” PMID 20350785 ↗ Mar 2010 |
| Route | Oral | “meloxicam oral suspension” NCT00034853 ↗ |
| Target | PTGS2 | “Cyclooxygenase-2 inhibitor” CHEMBL599 ↗ |